English
Regional settings| Spread | 0.032 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ €5,000.00 Short position overnight fee ~ €4,000.00 | -0.022099% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ €5,000.00 Short position overnight fee ~ €4,000.00 | -0.000123% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | EUR | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | Netherlands | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 0.868 |
| Open | 0.883 |
| 1-Year Change | -11.43% |
| Day's Range | 0.883 - 0.898 |
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
BRIEF: For the fiscal year ended 31 December 2021, Pharming Group N.V. revenues decreased 10% to EUR167.7M. Net income decreased 59% to EUR13.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income also reflects Research and development increase of 76% to EUR59.3M (expense), General and administrative increase of 48% to EUR31.2M (expense).
4/2010, Nominal value changed from EUR 0.5. 07/2012, Nominal value changed from EUR0.04. 3/2013, 1-for-10 reverse stock split (Factor: 0.1 ). 3/2013, Nominal value changed from EUR0.1 to EUR0.01. 11/2016, Rights Issue, 1 new share for every 7 shares held @ 0.205EUR, (Factor: 1.00751).
